05
STEP 1, SELECT, FLOW: semaglutide
A weight result gets more company here: another medicine, cardiovascular events and kidney disease. Each comparison has its own cast of participants.
Weight trials
In STEP 1, adults with overweight or obesity without diabetes had mean weight changes of -14.9% with semaglutide and -2.4% with placebo at 68 weeks. The placebo group’s loss helps establish the comparison around the medicine’s larger average change.
The SURMOUNT-5 trial compared semaglutide with tirzepatide in 751 adults with obesity. At 72 weeks, mean changes were -13.7% with semaglutide and -20.2% with tirzepatide. Tirzepatide produced greater mean weight loss in that direct comparison.
These trials let me ask two distinct questions: how semaglutide compares with placebo, and how it compares with another medicine. The semaglutide percentages came from different trials. Their difference cannot by itself explain why the averages varied or predict an individual response.
SELECT
SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the trial’s primary combined outcome of cardiovascular death, non-fatal heart attack or non-fatal stroke compared with placebo.
This is the result that gives the weight discussion additional seriousness for me. The investigators counted major clinical events in a defined population. They did more than assume a lower weight would carry every other benefit with it.
A combined outcome gathers several events into one analysis. Its improvement does not establish that every component changed by the same amount. Established cardiovascular disease and the absence of diabetes are also essential features of this trial’s population.
FLOW
FLOW studied 3,533 people with type 2 diabetes and chronic kidney disease. Semaglutide reduced a combined outcome covering kidney failure, a major decline in kidney function, or death from kidney or cardiovascular causes compared with placebo.
Here the people and the clinical question differ from SELECT. I give this kidney result its own space because describing it merely as another benefit of weight loss would discard the actual comparison. The trial studied people with both conditions and counted kidney-related outcomes directly.
Neither trial selects a treatment for an individual. They supply substantial evidence about specific medicines and specific groups.
GLP-1 and appetite
Semaglutide acts at the receptor for GLP-1, a hormone involved in blood-sugar regulation and appetite. It promotes insulin release when glucose rises, reduces inappropriate glucagon release, slows stomach emptying and influences appetite circuits. Chemical changes make its effects last longer than those of the natural hormone.
The appetite mechanism makes the weight findings understandable, while the safety review describes the digestive effects that accompany treatment. Mechanism and tolerability meet in the same subject.
People describe quieter hunger, earlier fullness, changed food preferences and fewer cravings. They also describe sulfur-smelling burps, reflux, fatigue, headache, dizziness and reactions at injection sites. Such accounts are anecdotal; they provide no controlled clinical estimate of how often an experience occurs or what caused it. I take these appetite accounts seriously; a controlled comparison would be needed to estimate frequency.
Safety findings
The dedicated semaglutide safety review judged the overall risk-benefit profile favourable in type 2 diabetes. Gastrointestinal effects, including nausea, vomiting, diarrhea and constipation, were generally mild to moderate and transient. Gallbladder disease was more frequent. That latter finding deserves space alongside the familiar stomach complaints.
Pancreatitis is a clinical warning, while pancreatic and thyroid-cancer signals remained uncertain because these events were rare. The warning concerning medullary thyroid carcinoma concerns that particular cancer; a family account of “thyroid cancer” alone does not identify its type. Pregnancy and pre-existing diabetic eye disease also matter to clinical assessment. Rapid improvement in blood sugar can worsen existing retinopathy.
I trust the major trial comparisons and take the cautions seriously. A strong benefit comparison makes the safety question more consequential, rather than making it disappear.
Approved products and the trial evidence
Approved semaglutide medicines have uses involving diabetes, weight management or cardiovascular risk in specified populations. Approval depends on the particular product and indication. A compounded or research-market preparation cannot inherit the manufactured medicine’s approval, verified contents or clinical evidence simply by sharing its ingredient name.
The trial results describe the products that were tested. Individual treatment requires assessment of medical history, other medicines and the actual preparation. Really Research Review offers no prescribing or product-selection service.
The comparison register places these trials beside the smaller and earlier experiments elsewhere in this review. Semaglutide has stronger human clinical evidence here, with outcomes that still need their full names.